Drugs / Lys-Arg
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT03972488 Background | Jan 2020 → Jul 2023 overdue | digestive system neuroendocrine neoplasm | Advanced Accelerator Applications | Active not recruiting | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lys-Arg | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03972488 ↗ |
| Route | Intravenous | “The 2.5% Lys-Arg solution was administered intravenously for 4 hours” NCT03972488 ↗ |